The estimated Net Worth of Jonathan Adam Feldschuh is at least $521 Тысяча dollars as of 15 March 2018. Mr Feldschuh owns over 19,194 units of Daxor stock worth over $35,719 and over the last 7 years he sold DXR stock worth over $357,584. In addition, he makes $127,920 as Chief Scientific Officer & Director at Daxor.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr Feldschuh DXR stock SEC Form 4 insiders trading
Mr has made over 1 trades of the Daxor stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 19,194 units of DXR stock worth $357,584 on 15 March 2018.
The largest trade he's ever made was selling 19,194 units of Daxor stock on 15 March 2018 worth over $357,584. On average, Mr trades about 6,398 units every 0 days since 2018. As of 15 March 2018 he still owns at least 3,908 units of Daxor stock.
You can see the complete history of Mr Feldschuh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Jonathan Adam Feldschuh biography
Jonathan Adam Feldschuh is the Chief Scientific Officer & Director at Daxor.
What is the salary of Mr Feldschuh?
As the Chief Scientific Officer & Director of Daxor, the total compensation of Mr Feldschuh at Daxor is $127,920. There are no executives at Daxor getting paid more.
How old is Mr Feldschuh?
Mr Feldschuh is 56, he's been the Chief Scientific Officer & Director of Daxor since . There are 5 older and 2 younger executives at Daxor. The oldest executive at Daxor Corp. is James Lombard, 80, who is the Independent Director.
What's Mr Feldschuh's mailing address?
Jonathan's mailing address filed with the SEC is 109 MECO LANE, , OAK RIDGE,, TN, 37830.
Insiders trading at Daxor
Over the last 21 years, insiders at Daxor have traded over $7,541,627 worth of Daxor stock and bought 473,408 units worth $2,888,339 . The most active insiders traders include Joseph Feldschuh, Bruce Slovin и Robert J Michel. On average, Daxor executives and independent directors trade stock every 39 days with the average trade being worth of $27,740. The most recent stock trade was executed by Robert J Michel on 27 March 2024, trading 750 units of DXR stock currently worth $6,525.
What does Daxor do?
the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.
What does Daxor's logo look like?
Complete history of Mr Feldschuh stock trades at Daxor
Daxor executives and stock owners
Daxor executives and other stock owners filed with the SEC include:
-
Jonathan Adam Feldschuh,
Chief Scientific Officer & Director -
Michael Richard Feldschuh,
Chairman, Pres & CEO -
Diane Meegan,
IR Contact Officer -
Robert Willens,
Independent Director -
James Lombard,
Independent Director -
Joy Goudie,
Independent Director -
Edward Feuer,
Director -
Henry Cremisi,
Director -
Jonathan Feldschuh,
Chief Scientific Officer, Director -
Robert Michel,
Chief Financial Officer -
Michael Feldschuh,
Chairman of the Board, President, Chief Executive Officer -
Robert J. Michel M.B.A., CPA, CPA,
CFO, Chief Compliance Officer & Corp. Sec. -
Guido Manzo,
VP of Sales -
Kathryn A. Kornafel,
VP of Marketing & Commercial Devel. -
Robert J. Michel M.B.A., C.P.A., CPA,
CFO, Chief Compliance Officer & Corp. Sec. -
Caleb Des Rosiers,
Director -
Of Joseph Feldschuh Estate,
10% owner -
Bernhard Saxe,
Director -
Soren Thompson,
VP, Business Development -
Everis Engstrom,
Vice President -
Robert G Moussa,
Director -
Martin S Wolpoff,
Director -
Philip Nordan Hudson,
Director -
Joseph Feldschuh,
President & CEO -
Stephen Valentine,
Director -
Bruce Slovin,
Director -
Gary Joseph Fischman,
President